Experimental drug offers hope for stubborn Tick-Borne infection
NCT ID NCT06478641
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program provides tafenoquine, an antimalarial drug, to immunocompromised patients with persistent babesiosis (a tick-borne illness) who haven't gotten better with standard treatments. Participants take the drug daily for 4 days, then weekly until they test negative for the parasite and symptoms resolve. The goal is to offer a potential treatment option for those at higher risk of complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tafenoquine (an antimalarial drug)
- What this could lead to
- If it works, this could offer a treatment option for immunocompromised patients with persistent babesiosis who have not responded to standard care.
- What could go wrong
- This is an expanded access program, not a formal trial, so evidence is limited. The drug may not work for everyone, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT BABESIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.